Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?

Pharmacological Research

Volumn 111, Issue , 2016, Pages 610-618

  Capron, A ^a,b   Haufroid, V ^a,b   Wallemacq, P ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; CALCINEURIN INHIBITOR; TARGET OF RAPAMYCIN KINASE;

CELL LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANTAGONISTS AND INHIBITORS; GRAFT REJECTION;

CALCINEURIN INHIBITORS; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; TOR SERINE-THREONINE KINASES;

EID: 84979695833     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.027     Document Type: Review

References (68)

1. [1] Wallemacq, P., Armstrong, V.W., Brunet, M., Haufroid, V., Holt, D.W., Johnston, A., Kuypers, D., Le Meur, Y., Marquet, P., Oellerich, M., Thervet, E., Toenshoff, B., Undre, N., Weber, L.T., Westley, I.S., Mourad, M., Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the european consensus conference. Ther. Drug Monit. 31 (2009), 139–152.
2. [2] Boudjema, K., Camus, C., Saliba, F., Calmus, Y., Salame, E., Pageaux, G., Ducerf, C., Duvoux, C., Mouchel, C., Renault, A., Compagnon, P., Lorho, R., Bellissant, E., Reduced-dose tacrolimus with mycophenolate mofetil vs: standard-dose tacrolimus in liver transplantation: a randomized study. Am. J. Transplant. 11 (2011), 965–976.
3. [3] Kahan, B.D., Keown, P., Levy, G.A., Johnston, A., Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin. Ther. 24 (2002), 330–350 (discussion 329).
4. [4] Starling, R.C., Hare, J.M., Hauptman, P., McCurry, K.R., Mayer, H.W., Kovarik, J.M., Schmidli, H., Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am. J. Transplant. 4 (2004), 2126–2131.
5. [5] Schiff, J., Cole, E., Cantarovich, M., Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephrol. 2 (2007), 374–384.
6. [6] Kuypers, D.R., Le Meur, Y., Cantarovich, M., Tredger, M.J., Tett, S.E., Cattaneo, D., Tonshoff, B., Holt, D.W., Chapman, J., Gelder, T., Transplantation Society Consensus Group on TDMoMPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephrol. 5 (2010), 341–358.
7. [7] Moes, D.J., Guchelaar, H.J., de Fijter, J.W., Sirolimus and everolimus in kidney transplantation. Drug Discov. Today 20 (2015), 1243–1249.
8. [8] Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D.C., Malaise, J., Lison, D., Squifflet, J.P., Wallemacq, P., The effect of cyp3a5 and mdr1 (abcb1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004), 147–154.
9. [9] Thervet, E., Anglicheau, D., Legendre, C., Beaune, P., Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit. 30 (2008), 143–150.
10. [10] Elie, V., de Beaumais, T., Fakhoury, M., Jacqz-Aigrain, E., Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. Pharmacogenomics 12 (2011), 827–843.
11. [11] Monchaud, C., de Winter, B.C., Knoop, C., Estenne, M., Reynaud-Gaubert, M., Pison, C., Stern, M., Kessler, R., Guillemain, R., Marquet, P., Rousseau, A., Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin. Pharmacokinet. 51 (2012), 175–186.
12. [12] Musuamba, F.T., Mourad, M., Haufroid, V., De Meyer, M., Capron, A., Delattre, I.K., Verbeeck, R.K., Wallemacq, P., Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br. J. Clin. Pharmacol. 75 (2013), 1277–1288.
13. [13] Gerard, C., Stocco, J., Hulin, A., Blanchet, B., Verstuyft, C., Durand, F., Conti, F., Duvoux, C., Tod, M., Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J. 16 (2014), 379–391.
14. [14] Coon, J.S., Wang, Y.Z., Bines, S.D., Markham, P.N., Chong, A.S., Gebel, H.M., Multidrug resistance activity in human lymphocytes. Hum. Immunol. 32 (1991), 134–140.
15. [15] Meaden, E.R., Hoggard, P.G., Khoo, S.H., Back, D.J., Determination of p-gp and mrp1 expression and function in peripheral blood mononuclear cells in vivo. J. Immunol. Methods 262 (2002), 159–165.
16. [16] Cascorbi, I., Role of pharmacogenetics of atp-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112 (2006), 457–473.
17. [17] Leschziner, G.D., Andrew, T., Pirmohamed, M., Johnson, M.R., Abcb1 genotype and pgp expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7 (2007), 154–179.
18. [18] Callaghan, R., Crowley, E., Potter, S., Kerr, I.D., P-glycoprotein: so many ways to turn it on. J. Clin. Pharmacol. 48 (2008), 365–378.
19. [19] Starkel, P., Sempoux, C., Van Den Berge, V., Stevens, M., De Saeger, C., Desager, J.P., Horsmans Y. Cyp 3a proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sci. 64 (1999), 643–653.
20. [20] Sallustio, B.C., Lc-ms/ms for immunosuppressant therapeutic drug monitoring. Bioanalysis 2 (2010), 1141–1153.
21. [21] Taylor, P.J., Tai, C.H., Franklin, M.E., Pillans, P.I., The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs. Clin. Biochem. 44 (2011), 14–20.
22. [22] Adaway, J.E., Keevil, B.G., Therapeutic drug monitoring and lc-ms/ms. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 883–884 (2012), 33–49.
23. [23] Lemaitre, F., Antignac, M., Verdier, M.C., Bellissant, E., Fernandez, C., Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going. Pharmacol. Res. 74 (2013), 109–112.
24. [24] Sandborn, W.J., Lawson, G.M., Cody, T.J., Porayko, M.K., Hay, J.E., Gores, G.J., Steers, J.L., Krom, R.A., Wiesner, R.H., Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of fk506 in hepatic tissue. Hepatology 21 (1995), 70–76.
25. [25] Capron, A., Lerut, J., Verbaandert, C., Mathys, J., Ciccarelli, O., Vanbinst, R., Roggen, F., De Reyck, C., Lemaire, J., Wallemacq, P.E., Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther. Drug Monit. 29 (2007), 340–348.
26. [26] Elens, L., Capron, A., Kerckhove, V.V., Lerut, J., Mourad, M., Lison, D., Wallemacq, P., Haufroid, V., 1199 > a and 2677 > t/a polymorphisms of abcb1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 17 (2007), 873–883.
27. [27] Noll, B.D., Coller, J.K., Somogyi, A.A., Morris, R.G., Russ, G.R., Hesselink, D.A., Van Gelder, T., Sallustio, B.C., Validation of an lc-ms/ms method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther. Drug Monit. 35 (2013), 617–623.
28. [28] Zahir, H., Nand, R.A., Brown, K.F., Tattam, B.N., McLachlan, A.J., Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J. Pharmacol. Toxicol. Methods 46 (2001), 27–35.
29. [29] Zahir, H., McCaughan, G., Gleeson, M., Nand, R.A., McLachlan, A.J., Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther. Drug Monit. 26 (2004), 506–515.
30. [30] Zahir, H., McCaughan, G., Gleeson, M., Nand, R.A., McLachlan, A.J., Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br. J. Clin. Pharmacol. 57 (2004), 298–309.
31. [31] Barbari, A., Masri, M., Stephan, A., Rizk, S., Khalil, L., Kamel, G., Tacrolimus lymphocyte vs blood trough level monitoring in de novo kidney transplant patients: clinical relevance. Exp. Clin. Transplant., 4, 2006, 58.
32. [32] Barbari, A., Masri, M., Stephan, A., Rizk, S., Younan, F., A novel approach in clinical immunosuppression monitoring: drug lymphocyte level. Exp. Clin. Transplant. 5 (2007), 643–648.
33. [33] Capron, A., Musuamba, F., Latinne, D., Mourad, M., Lerut, J., Haufroid, V., Wallemacq, P.E., Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther. Drug Monit. 31 (2009), 178–186.
34. [34] Capron, A., Mourad, M., De Meyer, M., De Pauw, L., Eddour, D.C., Latinne, D., Elens, L., Haufroid, V., Wallemacq, P., Cyp3a5 and abcb1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 11 (2010), 703–714.
35. [35] Dessilly, G., Elens, L., Panin, N., Capron, A., Decottignies, A., Demoulin, J.B., Haufroid, V., Abcb1 1199 genetic polymorphism (rs2229109) influences the intracellular accumulation of tacrolimus in hek293 and k562 recombinant cell lines. PLoS One, 9, 2014, e 91555.
36. [36] Capron, A., Lerut, J., Latinne, D., Rahier, J., Haufroid, V., Wallemacq, P., Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl. Int. 25 (2012), 41–47.
37. [37] Lemaitre, F., Antignac, M., Fernandez, C., Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clin. Biochem. 46 (2013), 1538–1541.
38. [38] Lemaitre, F., Blanchet, B., Latournerie, M., Antignac, M., Houssel-Debry, P., Verdier, M.-C., Dermu, M., Camus, C., Le Priol, J., Roussel, M., Zheng, Y., Fillatre, P., Curis, E., Bellissant, E., Boudjema, K., Fernandez, C., Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin. Biochem. 48 (2015), 406–411.
39. [39] Pensi, D., De Nicolo, A., Pinon, M., Calvo, P.L., Nonnato, A., Brunati, A., Di Perri, G., D'Avolio, A., An uplc-ms/ms method coupled with automated on-line spe for quantification of tacrolimus in peripheral blood mononuclear cells. J. Pharm. Biomed. Anal. 107 (2015), 512–517.
40. [40] Lensmeyer, G.L., Wiebe, D.A., Carlson, I.H., Distribution of cyclosporin a metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clin. Chem. 35 (1989), 56–63.
41. [41] Shibata, N., Shimakawa, H., Minouchi, T., Yamaji, A., Erythrocyte uptake and protein binding of cyclosporin a (cya) in human blood: factors affecting cya concentration in erythrocytes. Biol. Pharm. Bull. 16 (1993), 702–707.
42. [42] Akhlaghi, F., Trull, A.K., Distribution of cyclosporin in organ transplant recipients. Clin. Pharmacokinet. 41 (2002), 615–637.
43. [43] Sandborn, W.J., Lawson, G.M., Krom, R.A., Wiesner, R.H., Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 15 (1992), 1086–1091.
44. [44] Masri, M.A., Barbari, A., Stephan, A., Rizk, S., Kilany, H., Kamel, G., Measurement of lymphocyte cyclosporine levels in transplant patients. Transplant. Proc. 30 (1998), 3561–3562.
45. [45] Barbari, A., Masri, M.A., Stephan, A., Mokhbat, J., Kilani, H., Rizk, S., Kamel, G., Joubran, N., Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: correlation with histological findings. Transplant. Proc. 33 (2001), 2782–2785.
46. [46] Barbari, A., Stephan, A., Masri, M., Mourad, N., Kamel, G., Kilani, H., Karam, A., Daya, I.A., Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy. Transplant. Proc. 35 (2003), 2742–2744.
47. [47] Barbari, A.G., Masri, M.A., Stephan, A.G., Mourad, N., El-Ghoul, B., Kamel, G.S., Kilani, H.E., Karam, A.S., Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. Exp. Clin. Transplant. 3 (2005), 293–300.
48. [48] Barbari, A.G., Masri, M.A., Stephan, A.G., El Ghoul, B., Rizk, S., Mourad, N., Kamel, G.S., Kilani, H.E., Karam, A.S., Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study. Exp. Clin. Transplant. 4 (2006), 400–405.
49. [49] Lepage, J.M., Lelong-Boulouard, V., Lecouf, A., Debruyne, D., Hurault de Ligny, B., Coquerel, A., Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest: a prospective study on 20 renal transplant recipients. Transplant. Proc. 39 (2007), 3109–3110.
50. [50] Ansermot, N., Fathi, M., Veuthey, J.L., Desmeules, J., Hochstrasser, D., Rudaz, S., Quantification of cyclosporine a in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a column-switching approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857 (2007), 92–99.
51. [51] Ansermot, N., Rebsamen, M., Chabert, J., Fathi, M., Gex-Fabry, M., Daali, Y., Besson, M., Rossier, M., Rudaz, S., Hochstrasser, D., Dayer, P., Desmeules, J., Influence of abcb1 gene polymorphisms and p-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers. Drug Metab. Lett. 2 (2008), 76–82.
52. [52] Crettol, S., Venetz, J.P., Fontana, M., Aubert, J.D., Ansermot, N., Fathi, M., Pascual, M., Eap, C.B., Influence of abcb1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18 (2008), 307–315.
53. [53] Falck, P., Guldseth, H., Asberg, A., Midtvedt, K., Reubsaet, J.L., Determination of ciclosporin a and its six main metabolites in isolated t-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852 (2007), 345–352.
54. [54] Falck, P., Asberg, A., Guldseth, H., Bremer, S., Akhlaghi, F., Reubsaet, J.L., Pfeffer, P., Hartmann, A., Midtvedt, K., Declining intracellular t-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 85 (2008), 179–184.
55. [55] Falck, P., Asberg, A., Byberg, K.T., Bremer, S., Bergan, S., Reubsaet, J.L., Midtvedt, K., Reduced elimination of cyclosporine a in elderly (>65 years) kidney transplant recipients. Transplantation 86 (2008), 1379–1383.
56. [56] Robertsen, I., Falck, P., Andreassen, A.K., Naess, N.K., Lunder, N., Christensen, H., Gullestad, L., Asberg, A., Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin a in heart transplant recipients. Transpl. Res., 2, 2013, 5.
57. [57] Ventura-Aguiar, P., Campistol, J.M., Diekmann, F., Safety of mtor inhibitors in adult solid organ transplantation. Expert Opin. Drug Saf., 2016, 1–17.
58. [58] Masri, M., Rizk, S., Barbari, A., Stephan, A., Kamel, G., Rost, M., An assay for the determination of sirolimus levels in the lymphocyte of transplant patients. Transplant. Proc. 39 (2007), 1204–1206.
59. [59] Kloster-Jensen, K., Vethe, N.T., Bremer, S., Abadpour, S., Korsgren, O., Foss, A., Bergan, S., Scholz, H., Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. Transpl. Int. 28 (2015), 1152–1161.
60. [60] Roullet-Renoleau, F., Lemaitre, F., Antignac, M., Zahr, N., Farinotti, R., Fernandez, C., Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 66 (2012), 278–281.
61. [61] Robertsen, I., Vethe, N.T., Midtvedt, K., Falck, P., Christensen, H., Asberg, A., Closer to the site of action: everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations. Ther. Drug Monit. 37 (2015), 675–680.
62. [62] Benech, H., Hascoet, S., Furlan, V., Pruvost, A., Durrbach, A., Development and validation of an lc/ms/ms assay for mycophenolic acid in human peripheral blood mononuclear cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853 (2007), 168–174.
63. [63] Nguyen Thi, M.T., Capron, A., Mourad, M., Wallemacq, P., Mycophenolic acid quantification in human peripheral blood mononuclear cells using liquid chromatography–tandem mass spectrometry. Clin. Biochem. 46 (2013), 1909–1911.
64. [64] Thi, M.T., Mourad, M., Capron, A., Tshinanu, F.M., Vincent, M.F., Wallemacq, P., Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. Clin. Biochem. 48 (2015), 401–405.
65. [65] Md Dom, Z.I., Noll, B.D., Coller, J.K., Somogyi, A.A., Russ, G.R., Hesselink, D.A., van Gelder, T., Sallustio, B.C., Validation of an lc-ms/ms method for the quantification of mycophenolic acid in human kidney transplant biopsies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 945–946 (2014), 171–177.
66. [66] Saumet, A.M.T.F., Capron, A., Nguyen Thi, M.T., Wallemacq, P., Comparison of three methods for peripheral blood mononuclear cells separation. Ther. Drug Monit., 33, 2011, 1.
67. [67] Simiele, M., D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Agati, S., Cusato, J., Bonora, S., Di Perri, G., Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of hiv patients by a coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 55 (2011), 2976–2978.
68. [68] Ulmer, A.J., Flad, H.D., Discontinuous density gradient separation of human mononuclear leucocytes using percoll as gradient medium. J. Immunol. Methods 30 (1979), 1–10.